Researchers from Geneseeq and a network of Chinese academic hospitals have validated a blood test that can detect a broad range of cancers with high accuracy using cell-free DNA. A multi-cancer ...

Due to these benefits, the cell-free fetal DNA segment held the largest market share of 48.8% in the Global Cell-Free DNA (cfDNA) Testing Market in 2019.

Cell-free DNA analyses were accurate in detecting fetal antigen status as early as 10 weeks’ gestation in women with alloimmunized pregnancies, according to results of a large, diverse U.S ...

Combining AI-driven design with rapid, cell-free DNA synthesis, researchers are turning mRNA into a scalable solution for vaccines, cancer treatments, and personalized genetic therapies.

The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 2017;124:32-46.

Aldevron unveiled Alchemy™ cell-free DNA technology. The technology was designed to support development and preclinical programs, with a future cGMP offering expected to launch in 2025 to ...

Aldevron’s Alchemy™ is an exclusive cell-free DNA technology which cuts research grade linear DNA manufacturing time by over 50 percent, accelerating mRNA development projects with cleaner ...

Among liquid biopsy–based methodologies, cell-free DNA (cfDNA)–related early diagnosis technology is relatively mature, and relevant commercial detection kits have been approved. 8 The main ...

Researchers from Geneseeq and a network of Chinese academic hospitals have validated a blood test that can detect a broad range of cancers with high accuracy using cell-free DNA. A multi-cancer ...